Leaflet:information for the patient
Tamisten 5 mg film-coated tablets EFG
Tamisten 10 mg film-coated tablets EFG
Solifenacin succinate
Read the entire leaflet carefully before starting to take this medication,as it contains important information for you.
Contents of the leaflet
5 Conservation of Tamisten
The active ingredient of Tamisten belongs to the group of anticholinergics. These medications are used to reduce the activity of the overactive bladder. This allows you to have more time before needing to go to the bathroom and increases the amount of urine your bladder can hold.
Tamisten is used to treat the symptoms of overactive bladder syndrome. These symptoms include: having a strong and sudden need to urinate without warning, having to urinate frequently, or having urine leaks because you cannot reach the bathroom in time.
Do not take Tamisten:
Before starting treatment with Tamisten, inform your doctor if you have or have had any of the above-mentioned diseases.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Tamisten:
Before starting treatment with Tamisten, inform your doctor if you have or have had any of the above-mentioned diseases.
Before starting treatment with Tamisten, your doctor will assess if there are other causes for your frequent need to urinate (e.g., heart failure or kidney disease).
If you have a urinary tract infection, your doctor will prescribe an antibiotic (treatment against certain bacterial infections).
Children and adolescents
Tamisten should not be used in children or adolescents under 18 years of age (see section 3).
Other medications and Tamisten
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication. It is especially important that you inform your doctor if you are taking:
Taking Tamisten with food and drinks
Tamisten can be taken with or without food, as you prefer.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
You should not use Tamisten if you are pregnant unless it is absolutely necessary.
Do not use Tamisten during breastfeeding, as solifenacin may pass into breast milk.
Driving and using machines
Solifenacin may cause blurred vision and, sometimes, drowsiness or fatigue. If you experience any of these side effects, do not drive or use machines.
Follow your doctor's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again.
The recommended dose is 5 mg per day, unless your doctor tells you to take 10 mg per day.
Swallow the tablet whole with some liquid. It can be taken with or without food, as you prefer. Do not crush the tablets.
Use in children and adolescents
Tamisten should not be used in children or adolescents under 18 years of age.
If you take more Tamisten than you should
If you have taken too much Tamisten or if a child has accidentally taken Tamisten, contact your doctor or pharmacist immediately, or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested. The symptoms in case of overdose may include: headache, dry mouth, dizziness, drowsiness, and blurred vision, perception of things that are not there (hallucinations), excessive excitement, convulsions, difficulty breathing, increased heart rate (tachycardia), accumulation of urine in the bladder (urinary retention), and dilation of the pupils (mydriasis).
If you forget to take Tamisten
If you forget to take a dose at the usual time, take it as soon as you remember, unless it is time to take the next dose.
Do not take a double dose to make up for forgotten doses. If you have any doubts, always consult your doctor or pharmacist.
If you stop taking Tamisten
If you stop taking this medication, your overactive bladder symptoms may return or worsen. Always consult your doctor if you are considering stopping treatment.
If you have any other questions about using this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
If you suffer an allergic reaction or a severe skin reaction (e.g., blistering and peeling of the skin), inform your doctor or pharmacist immediately.
Angioedema (allergic reaction in the skin that results in inflammation under the skin's surface) with respiratory tract obstruction (difficulty breathing) has been reported in some patients treated with solifenacin succinate. In case of angioedema, treatment with solifenacin (Tamisten) should be discontinued immediately, and appropriate therapy and/or measures should be initiated.
Solifenacin may cause the following side effects:
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1000 people):
Very rare(may affect up to 1 in 10,000 people):
Frequency not known(frequency cannot be estimated from available data):
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date stated on the box, after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the Sigre collection point in the pharmacy. This will help protect the environment.
Composition ofTamisten
Appearance of the product and package contents
Tamisten 5 mg tablets are yellow, round, biconvex film-coated tablets with a diameter of 6 mm.
Tamisten 10 mg tablets are red, round, biconvex film-coated tablets with a diameter of 8 mm.
The package contains transparent PVC/PVDC-Alu blister packs and aluminum blister packs with a push-through opening, containing 10, 20, 30, 50, 60, 90, or 100 tablets.
Only certain package sizes may be marketed.
Marketing authorization holder and manufacturer
Medochemie Ltd
1-10 Constantinoupoleos street
3011 Limassol,
Cyprus
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Medochemie Iberia S.A., Spanish branch
Avenida de las Águilas, nº 2 B; 5th floor, office 6,
28044 Madrid
SPAIN
This medication is authorized in the member states of the European Economic Area under the following names:
Estonia | TAMISTEN |
Bulgaria | VESIMED |
Croatia | FOLINAR |
Cyprus | VEZIMED |
Czech Republic | FOLINAR |
Greece | VILAND |
Latvia | TAMISTEN |
Lithuania | TAMISTEN |
Malta | VEZIMED |
Romania | VEZIMED |
Slovak Republic | FOLINAR |
Slovenia | TAMISTEN |
Spain | TAMISTEN |
Latvia | TAMISTEN |
Date of the last revision of this leaflet: June 2021.
The average price of TAMISTEN 5 mg FILM-COATED TABLETS in October, 2025 is around 20.4 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.